| Literature DB >> 35039559 |
Rémi Palmier1, Thibault Degand1, Serge Aho2, Côme Lepage1, Olivier Facy3, Christophe Michiels1, Sylvain Manfredi4,5.
Abstract
Many studies identified colonoscopy quality indicators in order to improve performance and safety. We conducted a colonoscopy improvement study. Our study was designed according to a Plan-Do-Study-Act cycle: first recording of our quality indicators and identification of shortcomings, second identification of improvement targets and implementation of new procedures, third second recording of quality indicators, fourth validation of procedures and identification of new goals. Quality indicators derived from European and French guidelines were recorded before and after our improvement actions. We were mainly interested in the quality indicators of the colonic preparation, the description of the diagnosed lesions and on the examination reports. The data of 134 patients prospectively included in January-February 2017 were compared to 133 patients included in May-June 2019, after implementation of improvement procedures, in the digestive endoscopy unit of the university hospital of Dijon, France. Our intervention, and in particular the implementation of new standardized forms, improved preparation quality: Boston Bowel Preparation Scale scores increased significantly from 7.8 to 8.2. Cecal intubation rate increased by 6%, and more adenomas were diagnosed and removed (+3.3%). Adenoma detection rate increased significantly from 26 to 42%. The completion of withdrawal time measure improved from 6.7 to 100%. Our study led to the rapid implementation of corrective actions and improved quality in our unit and in our personal practice. This quality improvement strategy could be easily implemented in every digestive endoscopy unit.Entities:
Mesh:
Year: 2022 PMID: 35039559 PMCID: PMC8763865 DOI: 10.1038/s41598-022-04786-y
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Population characteristics.
| Phase 1 | Phase 2 | ||||
|---|---|---|---|---|---|
| n = 134 | (%) | n = 133 | (%) | ||
| Men | 73 | 54.5 | 66 | 49.6 | 0.43 |
| Women | 61 | 45.5 | 67 | 50.4 | |
| Outpatients | 89 | 66.4 | 91 | 68.5 | 0.06 |
| GE inpatients | 22 | 16.3 | 32 | 24.0 | |
| Non GE inpatients | 23 | 17.3 | 10 | 7.5 | |
| General practitioner | 40 | 29.9 | 57 | 42.9 | 0.06 |
| Own gastroenterologist | 53 | 39.5 | 37 | 27.8 | |
| Other gastroenterologist | 1 | 0.7 | 3 | 2.2 | |
| Other specialist | 40 | 29.9 | 36 | 27.1 | |
| FIT | 30 | 22.4 | 6 | 4.5 | 0.02 |
| Symptoms | 52 | 38.8 | 48 | 36.1 | |
| IBD | 15 | 11.2 | 17 | 12.8 | |
| Personal history | 11 | 8.2 | 26 | 19.6 | |
| Familial antecedent | 15 | 11.2 | 13 | 9.8 | |
| Other (before surgery) | 11 | 8.2 | 23 | 17.2 | |
FIT: Fecal immunological test, IBD: inflammatory bowel disease, BMI: body mass index, SD: standard deviation, GE: gastroenterology.
Bowel preparations and time to colonoscopy.
| Phase 1 | Phase 2 | ||||
|---|---|---|---|---|---|
| N = 134 | (%) | N = 133 | (%) | ||
| PEG 4 L | 36 | 26.9 | 2 | 1.5 | 0.0001 |
| PEG 2 L + ascorbic acid | 68 | 50.7 | 115 | 86.5 | |
| Sodium phosphate drinkable | 3 | 2.2 | 0 | 0.0 | |
| Sodium phosphate tablets | 1 | 0.8 | 3 | 2.2 | |
| Sodium Picosulfate | 25 | 18.6 | 11 | 8.3 | |
| Enemas | 1 | 0.8 | 2 | 1.5 | |
| None | 24 | 17.9 | 4 | 3 | 0.0001 |
| 2 takes one day before | 74 | 55.2 | 0 | 0 | |
| Split dosing | 36 | 26.9 | 128 | 97 | |
| Morning | 122 | 91 | 113 | 85 | 0.13 |
| Afternoon | 12 | 9 | 20 | 15 | |
| n = 105 | N = 131 | ||||
| 3–5 h | 26 | 24.8 | 125 | 95.4 | 0.0001 |
| 5–8 h | 3 | 2.8 | 3 | 2.3 | |
| > 8 h | 76 | 72.4 | 3 | 2.3 | |
| n = 70 | 69 | ||||
| Excellent | 3 | 4.3 | 8 | 11.6 | 0.9 |
| Good | 59 | 85.3 | 56 | 81.2 | |
| Middle | 5 | 7.1 | 3 | 4.3 | |
| Bad | 3 | 4.3 | 2 | 2.9 | |
| Very bad | 0 | 0.0 | 0 | 0.0 | |
FIT: Fecal immunological test, GE: gastroenterologist, IQR: interquartile range, PEG: polyethylene glycol.
BBPS and colonoscopy results.
| Phase 1 | Phase 2 | ||||
|---|---|---|---|---|---|
| n | (%) | n | (%) | ||
| Completion in report | 105 | 84 | 123 | 99 | 0.0001 |
| BBPS > 6 (SFED) | 98 | 93 | 119 | 97 | 0.002 |
| BBPS > 7 (ESGE) | 84 | 80 | 109 | 88 | |
| 7.76 | 8.22 | 0.007 | |||
| Normal | 44 | 32.8 | 50 | 37.6 | 0.02 |
| Polypes | 50 | 37.3 | 54 | 40.6 | |
| Malignancy | 7 | 5.2 | 1 | 0.8 | |
| Diverticulosis | 15 | 11.2 | 11 | 8.3 | |
| Active IBD | 8 | 6 | 15 | 11.3 | |
| Others* | 10 | 7.5 | 2 | 1.5 | |
| Yes | 113 | 84.3 | 120 | 90.2 | 0.15 |
| No | 21 | 15.7 | 13 | 9.8 | |
| Failure | |||||
| Technical reasons | 4 | 25 | 6 | 60 | 0.09 |
| Bad preparation | 12 | 75 | 4 | 40 | |
BBPS: boston bowel preparation scale, SFED: French society of digestive endoscopy, ESGE: European society of gastrointestinal endoscopy, IBD: inflammatory bowel disease.
*2 angiodysplasia, 2 infectious colitis, 2 post-radiation colitis, 1 ischemic colitis and 3 unclassified colitis. Significant values are in bold.
Figure 1Boston Bowel Preparation Scale distribution.
Histology and adenoma detection rate.
| Phase 1 | Phase 2 | ||||
|---|---|---|---|---|---|
| n = 131 | (%) | n = 132 | (%) | ||
| 0.003 | |||||
| Hyperplastic | 18 | 32.7 | 6 | 10.9 | |
| Adenoma | 30 | 54.5 | 48 | 87.3 | |
| Adenocarcinoma | 7 | 12.8 | 1 | 1.8 | |
| PDR | 55 | 38.0 | 55 | 41.0 | 0.5 |
| ADR | 30 | 25.8 | 48 | 41.7 | 0.01 |
| FIT detection rates | |||||
| ADR | 15 | 50.0 | 5 | 83.3 | 0.12 |
*After exclusion of patients with IBD and emergency situations (n = 15 in phase 1 and n = 17 in phase 2).
PDR: Polyp detection rate, ADR: adenoma detection rate. Significant values are in bold.